96 related articles for article (PubMed ID: 17728181)
1. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels.
Hessel MH; Bleeker GB; Bax JJ; Henneman MM; den Adel B; Klok M; Schalij MJ; Atsma DE; van der Laarse A
Eur J Heart Fail; 2007 Oct; 9(10):1058-63. PubMed ID: 17728181
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy.
Franz M; Berndt A; Altendorf-Hofmann A; Fiedler N; Richter P; Schumm J; Fritzenwanger M; Figulla HR; Brehm BR
Eur J Heart Fail; 2009 Nov; 11(11):1057-62. PubMed ID: 19815660
[TBL] [Abstract][Full Text] [Related]
3. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial.
Daubert C; Gold MR; Abraham WT; Ghio S; Hassager C; Goode G; Szili-Török T; Linde C;
J Am Coll Cardiol; 2009 Nov; 54(20):1837-46. PubMed ID: 19800193
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis.
van Bommel RJ; Bax JJ; Abraham WT; Chung ES; Pires LA; Tavazzi L; Zimetbaum PJ; Gerritse B; Kristiansen N; Ghio S
Eur Heart J; 2009 Oct; 30(20):2470-7. PubMed ID: 19717847
[TBL] [Abstract][Full Text] [Related]
5. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony.
Fruhwald FM; Fahrleitner-Pammer A; Berger R; Leyva F; Freemantle N; Erdmann E; Gras D; Kappenberger L; Tavazzi L; Daubert JC; Cleland JG
Eur Heart J; 2007 Jul; 28(13):1592-7. PubMed ID: 17298973
[TBL] [Abstract][Full Text] [Related]
6. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
Orn S; Manhenke C; Squire IB; Ng L; Anand I; Dickstein K
J Card Fail; 2007 Dec; 13(10):843-9. PubMed ID: 18068618
[TBL] [Abstract][Full Text] [Related]
7. Neurohormones and inflammatory mediators in patients with heart failure undergoing cardiac resynchronization therapy: time courses and prediction of response.
Boriani G; Regoli F; Saporito D; Martignani C; Toselli T; Biffi M; Francolini G; Diemberger I; Bacchi L; Rapezzi C; Ferrari R; Branzi A
Peptides; 2006 Jul; 27(7):1776-86. PubMed ID: 16621149
[TBL] [Abstract][Full Text] [Related]
8. Feasibility, safety, and mid-term efficacy of cardiac resynchronization therapy in patients with severe heart failure and ventricular conduction delay: Chulalongkorn experience.
Sunsaneewitayakul B; Sitthisook S; Sangwatanaroj S; Prechawat S; Songmuang SB
J Med Assoc Thai; 2007 Jul; 90(7):1458-66. PubMed ID: 17710992
[TBL] [Abstract][Full Text] [Related]
9. Effects of cardiac resynchronization therapy on systemic inflammation and neurohormonal pathways in heart failure.
Tarquini R; Guerra CT; Porciani MC; Michelucci A; Padeletti M; Ricciardi G; Chiostri M; Jelic S; Padeletti L
Cardiol J; 2009; 16(6):545-52. PubMed ID: 19950091
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study.
Linde C; Gold M; Abraham WT; Daubert JC;
Am Heart J; 2006 Feb; 151(2):288-94. PubMed ID: 16442890
[TBL] [Abstract][Full Text] [Related]
11. Adrenomedullin plasma levels predict left ventricular reverse remodeling after cardiac resynchronization therapy.
Morales MA; Maltinti M; Piacenti M; Turchi S; Giannessi D; Del Ry S
Pacing Clin Electrophysiol; 2010 Jul; 33(7):865-72. PubMed ID: 20230463
[TBL] [Abstract][Full Text] [Related]
12. Cardiac resynchronization therapy-induced left ventricular reverse remodelling is associated with reduced plasma annexin A5.
Ravassa S; García-Bolao I; Zudaire A; Macías A; Gavira JJ; Beaumont J; Arias T; Huerta A; Díez J
Cardiovasc Res; 2010 Nov; 88(2):304-13. PubMed ID: 20542876
[TBL] [Abstract][Full Text] [Related]
13. Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.
Milting H; Ellinghaus P; Seewald M; Cakar H; Bohms B; Kassner A; Körfer R; Klein M; Krahn T; Kruska L; El Banayosy A; Kramer F
J Heart Lung Transplant; 2008 Jun; 27(6):589-96. PubMed ID: 18503956
[TBL] [Abstract][Full Text] [Related]
14. Differential change in left ventricular mass and regional wall thickness after cardiac resynchronization therapy for heart failure.
Zhang Q; Fung JW; Auricchio A; Chan JY; Kum LC; Wu LW; Yu CM
Eur Heart J; 2006 Jun; 27(12):1423-30. PubMed ID: 16682380
[TBL] [Abstract][Full Text] [Related]
15. Toward understanding response to cardiac resynchronization therapy: left ventricular dyssynchrony is only one of multiple mechanisms.
Parsai C; Bijnens B; Sutherland GR; Baltabaeva A; Claus P; Marciniak M; Paul V; Scheffer M; Donal E; Derumeaux G; Anderson L
Eur Heart J; 2009 Apr; 30(8):940-9. PubMed ID: 19004844
[TBL] [Abstract][Full Text] [Related]
16. Repercussion of functional mitral regurgitation on reverse remodelling in cardiac resynchronization therapy.
Cabrera-Bueno F; García-Pinilla JM; Peña-Hernández J; Jiménez-Navarro M; Gómez-Doblas JJ; Barrera-Cordero A; Alzueta-Rodríguez J; de Teresa-Galván E
Europace; 2007 Sep; 9(9):757-61. PubMed ID: 17573358
[TBL] [Abstract][Full Text] [Related]
17. Recoordination rather than resynchronization predicts reverse remodeling after cardiac resynchronization therapy.
Wang CL; Wu CT; Yeh YH; Wu LS; Chang CJ; Ho WJ; Hsu LA; Luqman N; Kuo CT
J Am Soc Echocardiogr; 2010 Jun; 23(6):611-20. PubMed ID: 20418055
[TBL] [Abstract][Full Text] [Related]
18. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
19. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy.
Aso N; Tamura A; Nasu M
Am J Cardiol; 2004 Dec; 94(11):1468-70. PubMed ID: 15566931
[TBL] [Abstract][Full Text] [Related]
20. Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure.
Fujimoto N; Onishi K; Sato A; Terasaki F; Tsukada B; Nozato T; Yamada T; Imanaka-Yoshida K; Yoshida T; Ito M; Hiroe M
J Card Fail; 2009 Dec; 15(10):898-905. PubMed ID: 19944367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
